Dr Habeebullah Life Sciences Ltd
BSE:539267
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (1 184.7), the stock would be worth ₹0 (100% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | ₹16.38 |
0%
|
| 3-Year Average | 1 184.7 | ₹0 |
-100%
|
| 5-Year Average | 1 184.7 | ₹0 |
-100%
|
| Industry Average | 6.3 | ₹0 |
-100%
|
| Country Average | 2.6 | ₹0 |
-100%
|
Forward P/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
D
|
Dr Habeebullah Life Sciences Ltd
BSE:539267
|
372.6m INR | 0 | -4.7 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 327.8 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
173.3B USD | 3.8 | 25.3 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.5B USD | 5.1 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 18.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
331.7B CNY | 7.1 | 16.8 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.5B CHF | 5 | -118.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.5B USD | 4.5 | 24.4 | |
| US |
|
Waters Corp
NYSE:WAT
|
28.7B USD | 9.1 | 44.6 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.6B USD | 1.6 | 19.6 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.2B USD | 6.3 | 29 |
Market Distribution
Other Multiples
Dr Habeebullah Life Sciences Ltd
Glance View
Dr Habeebullah Life Sciences Ltd. is an India-based company. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2015-08-10. The firm is engaged in research and development (R&D), trading, import and exports, and R&D services of bioproducts and pharma products. The firm's products and R&D include Stem Cell R&D, New Drug Discovery, ribonucleic acid (RNA) Interference, Molecular Biomarkers and Medical Devices. Its Stem Cell R&D division specializes in stem cell research and therapy, regenerative medicine, bio-artificial organ scaffolds development, nanobiotechnology, nano formulation of cancer drugs, molecular genetics, and molecular virology, stem cell and cord blood banking. Its New Drug Discovery division is focused on working on five therapeutic areas of Wilson’s disease, non-alcoholic steatohepatitis (NASH), neuropathic pain, cardiovascular diseases, cystinosis and Huntington's disease. Its services include molecular diagnostics, stem cell therapy, clinical services, contract research organization and academic services.
